Claris Bio

Claris Bio announced $118M in Series B financing on July 28, 2026. Claris Bio closed a $118 million Series B co-led by Samsara Biocapital and Catalio Capital Management to fund trials and a planned pivotal program in limbal stem cell deficiency.

Round details

The financing includes backing from Samsara Biocapital, Catalio Capital Management, Novo Holdings, Janus Henderson Investors, Mass General Brigham Ventures, Adage Capital Management, Sofinnova Investments, Aisling Capital. The company did not publish a valuation with the announcement.

• Round: Series B
• Capital announced: $118M

How the company plans to use the capital

Claris said proceeds will be used to complete its ongoing clinical trials in patients with limbal stem cell deficiency and to fund the company through a planned pivotal program of CSB-001. The financing will also enable pre-commercialization activities.

Why this matters for GTM teams

The round pairs two new co-lead investors with continued support from all existing investors as the company moves from ongoing trials toward planned pivotal studies in the first half of 2027.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Claris Bio Series B announcement.